Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches.

Although oral vaccination has numerous advantages over parenteral injection, degradation of the vaccine in the gut and low uptake in the lymphoid tissue of the gastrointestinal tract still complicate the development of oral vaccines. In this study chitosan microparticles were prepared and characterized with respect to size, zeta potential, morphology and ovalbumin-loading and -release. Furthermore, the in vivo uptake of chitosan microparticles by murine Peyer's patches was studied using confocal laser scanning microscopy (CLSM). Chitosan microparticles were made according to a precipitation/coacervation method, which was found to be reproducible for different batches of chitosan. The chitosan microparticles were 4.3+/-0.7 microm in size and positively charged (20+/-1 mV). Since only microparticles smaller than 10 microm can be taken up by M-cells of Peyer's patches, these microparticles are suitable to serve as vaccination systems. CLSM visualization studies showed that the model antigen ovalbumin was entrapped within the chitosan microparticles and not only associated to their outer surface. These results were verified using field emission scanning electron microscopy, which demonstrated the porous structure of the chitosan microparticles, thus facilitating the entrapment of ovalbumin in the microparticles. Loading studies of the chitosan microparticles with the model compound ovalbumin resulted in loading capacities of about 40%. Subsequent release studies showed only a very low release of ovalbumin within 4 h and most of the ovalbumin (about 90%) remained entrapped in the microparticles. Because the prepared chitosan microparticles are biodegradable, this entrapped ovalbumin will be released after intracellular digestion in the Peyer's patches. Initial in vivo studies demonstrated that fluorescently labeled chitosan microparticles can be taken up by the epithelium of the murine Peyer's patches. Since uptake by Peyer's patches is an essential step in oral vaccination, these results show that the presently developed porous chitosan microparticles are a very promising vaccine delivery system.

[1]  A. Jayakrishnan,et al.  Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[2]  J. Kreuter,et al.  Influence of crosslinking on the acid stability and physicochemical properties of chitosan microspheres , 1996 .

[3]  C. Ruedl,et al.  Oral immunization with poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres containing pneumotropic bacterial antigens. , 1997, International archives of allergy and immunology.

[4]  L. Illum,et al.  Chitosan and its use as a pharmaceutical excipient. , 1998, Pharmaceutical research.

[5]  R. Muzzarelli,et al.  Human enzymatic activities related to the therapeutic administration of chitin derivatives , 1997, Cellular and Molecular Life Sciences CMLS.

[6]  G. Russell-Jones,et al.  Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding , 1988, The Journal of experimental medicine.

[7]  R. Mrsny,et al.  In Vitro Evaluation of Microparticles and Polymer Gels for Use as Nasal Platforms for Protein Delivery , 1999, Pharmaceutical Research.

[8]  H. Greenberg,et al.  Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles , 1998, Journal of Virology.

[9]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[10]  R. Rappuoli,et al.  Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. , 1998, Vaccine.

[11]  M. Alonso,et al.  Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers , 1997 .

[12]  Thomas R. Tice,et al.  Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .

[13]  J. Eyles,et al.  Oral and nasal immunization with microencapsulated clinically relevant proteins , 1998 .

[14]  A. Fasano,et al.  Innovative strategies for the oral delivery of drugs and peptides. , 1998, Trends in biotechnology.

[15]  M. Alonso,et al.  Design of microencapsulated chitosan microspheres for colonic drug delivery. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[16]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[17]  W. Shalaby Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies. , 1995, Clinical immunology and immunopathology.

[18]  J. Kreuter,et al.  Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs , 1996 .

[19]  J. Kreuter Nanoparticles and microparticles for drug and vaccine delivery. , 1996, Journal of anatomy.